Investigators from the Dominantly Inherited Alzheimer Network have published the design of DIAN-TU-002, described as the first platform trial to give an anti-amyloid drug to people carrying dominantly inherited Alzheimer's mutations before amyloid plaques are detectable. The perspective and design paper appeared in npj Dementia on June 1, 2026. It states that the trial enrols mutation carriers 25 to 11 years before their estimated age of symptom onset, a window derived from the age at which an affected parent first became symptomatic. The registration for the first drug arm, testing the investigational Eli Lilly antibody remternetug, is a Phase 2/3 randomised, quadruple-masked, placebo-controlled study with an estimated 280 participants, minimum age 18, which began on November 22, 2024 and lists estimated completion in August 2034 under master protocol NCT05552157.
The published design fixes what will count as success in people who may be two decades from symptoms. Stage 1's primary outcome is change in brain amyloid load in centiloids measured by [11C]PiB PET, with the registry listing assessment from baseline to week 192. The authors identify 16.3 centiloids as the level at which amyloid PET begins to rise reliably each year, and treat crossing that level as the event of interest; the paper says an unblinded team will reallocate placebo-assigned participants above 16.3 centiloids to remternetug once they reach year two, after the biomarker assessment that feeds the Stage 1 outcome. Stage 2 moves to downstream markers, with the registry describing an odds ratio between treated and control groups of occupying a lower biomarker progression stage on modelling of six measures, including tau markers, CSF neurofilament light and MRI volume.
The reliance on biomarkers is explained in the paper itself: in a population at this stage of disease, the authors estimate a minimum of 10 to 15 years will elapse before enough participants reach the earliest symptomatic stage. That is the trade the design makes, and the reason the paper matters beyond this one trial: prevention programmes that begin before pathology is measurable cannot wait for dementia to count outcomes, and this is the first published template for doing so in a genetically determined population.
The authors set out the limits of their own approach. They estimate that roughly 30 per cent of mutation carriers in the 25 to 11 year window will already have elevated amyloid PET at enrolment, which they say does not represent true primary prevention, though they argue it adds efficiency within a single trial. Stage 2 compares participants not with a randomised placebo group but with external comparators drawn from the DIAN observational natural history study and placebo-treated participants from the earlier DIAN-TU-001 trial. Remternetug remains investigational and is not an approved treatment.